BRAF and melanoma: In the phase III KEYNOTE-006 trial, in which patients with BRAF wild-type and BRAF-mutant melanoma were randomized to first-line pembrolizumab or ipilimumab, among patients with BRAF-mutant melanoma, those who had not been treated previously with a BRAFi had longer mPFS than patients who had received previous BRAFi treatment (7.0 vs. 2.8 months; 6-month PFS rate: 52.7% vs. 32.2%) [42].